Erenumab For Treatment of Hemicrania Continua
NCT04303845
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class
Stopped
difficulty with recruitment
Conditions
Hemicrania Continua
Interventions
DRUG:
Erenumab
Sponsor
Mayo Clinic